Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request

REDUCTION OF TRAF1 LEVELS COMBINED WITH NUTRIENT STRESS FOR TREATING LYMPHOCYTE-RELATED CANCERS

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
اقرأ أكثر حفظ في قائمتي
  • Publication Date:
    December 15, 2016
  • معلومة اضافية
    • Document Number:
      20160361391
    • Appl. No:
      15/121563
    • Application Filed:
      March 06, 2015
    • نبذة مختصرة :
      The present disclosure provides methods and uses for treating lymphocyte related cancers comprising administering a nutrient stress-inducing agent in combination with an agent that lowers the levels of or inhibits TRAF1. Also provided are methods of determining treatment for a subject with a lymphocyte related cancer and assays for identifying a PKN1 inhibitor.
    • Claim:
      1. A method of treating a lymphocyte related cancer in a subject comprising administering a nutrient stress inducing agent in combination with an agent that lowers the levels of or inhibits TRAF1 to the subject in need thereof.
    • Claim:
      2. The method of claim 1, wherein the lymphocyte related cancer is lymphoma or leukemia.
    • Claim:
      3. (canceled)
    • Claim:
      4. The method of claim 1, wherein the nutrient stress inducing agent is asparaginase or arginase.
    • Claim:
      5. The method of claim 4, wherein the asparaginase is Erwinase.
    • Claim:
      6. (canceled)
    • Claim:
      7. The method of claim 1, wherein the agent that lowers the levels of or inhibits TRAF1 is an antisense or shRNA to TRAF1 or is a TRAF1 antibody.
    • Claim:
      8. The method of claim 7, wherein the shRNA comprises the nucleotide sequence as shown in SEQ ID NO:1 or a variant thereof.
    • Claim:
      9. The method of claim 1, wherein the agent that lowers the levels of or inhibits TRAF1 is a PKN1 inhibitor.
    • Claim:
      10. The method of claim 9, wherein the PKN1 inhibitor is an antisense or shRNA to PKN1 or is a PKN1 antibody.
    • Claim:
      11. The method of claim 10, wherein the shRNA comprises the nucleotide sequence as shown in SEQ ID NO:2 or a variant thereof.
    • Claim:
      12. (canceled)
    • Claim:
      13. A method of determining treatment for a lymphocyte-related cancer in a subject comprising: determining whether the lymphocyte-related cancer is TRAF1 low or TRAF1 high by comparing to a control; wherein if the lymphocyte related cancer is TRAF1 low it is indicative of treating the subject with a nutrient stress inducing agent; and wherein if the lymphocyte related cancer is TRAF1 high, it is indicative of treating the subject with a nutrient stress inducing agent in combination with an agent that lowers the levels of or inhibits TRAF1.
    • Claim:
      14. A method of determining treatment for a lymphocyte-related cancer in a subject comprising: a) determining whether the lymphocyte-related cancer is TRAF1 low or TRAF1 high by comparing to a control; b) treating the subject with a nutrient stress inducing agent if the subject is TRAF1 low; and c) treating the subject with a nutrient stress inducing agent in combination with an agent that lowers the levels of or inhibits TRAF1 if the subject is TRAF1 high.
    • Claim:
      15. The method of claim 13, wherein the control is a TRAF1 high control from the same type of tumour or from a pool of positive tumours of the same type or wherein the control is a TRAF1 low control from a cell line of a similar type of tumour that has been treated with shPKN1 or shTRAF1.
    • Claim:
      16. (canceled)
    • Claim:
      17. (canceled)
    • Claim:
      18. The method of claim 13 wherein determining whether the lymphocyte-related cancer is TRAF1 low or TRAF1 high comprises measuring the expression of TRAF1 from a sample.
    • Claim:
      19. The method of claim 18, wherein determining whether the cancer is TRAF1 low or TRAF1 high further comprises assaying the expression level of Raji control cells or Daudi control cells at the same time as measuring the level of TRAF1 in the sample.
    • Claim:
      20. The method of claim 18, wherein the sample is peripheral blood mononuclear cells, whole blood samples or from a biopsy.
    • Claim:
      21. (canceled)
    • Claim:
      22. The method of claim 13, wherein the nutrient stress-inducing agent is an asparaginase, arginase or glutaminase.
    • Claim:
      23. The method of claim 22, wherein the nutrient stress-inducing agent is Erwinase.
    • Claim:
      24. The method of claim 13, wherein the lymphocyte related cancer is lymphoma or leukemia.
    • Claim:
      25. (canceled)
    • Claim:
      26. (canceled)
    • Claim:
      27. (canceled)
    • Current International Class:
      61; 12; 01; 61
    • الرقم المعرف:
      edspap.20160361391